GSK PLC (GS71.HA)
Hanover - Hanover Delayed price. Currency in EUR
Add to watchlist
At close: 08:16AM CEST
| Previous close | 18.21 |
| Open | 18.12 |
| Bid | 17.97 x N/A |
| Ask | 18.06 x N/A |
| Day's range | 18.12 - 18.12 |
| 52-week range | 15.36 - 20.99 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
PHILADELPHIA, June 07, 2024--US FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk
- Business Wire
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
PHILADELPHIA, June 03, 2024--Jemperli trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced dMMR rectal cancer
- Business Wire
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
PHILADELPHIA, June 02, 2024--Belantamab Mafodotin combo reduced the risk of disease progression or death by nearly 50% versus SOC combo in relapsed/refractory multiple myeloma
© 2024 Yahoo. All rights reserved.